Metyrapone
- Generic Name
- Metyrapone
- Brand Names
- Metopirone
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14N2O
- CAS Number
- 54-36-4
- Unique Ingredient Identifier
- ZS9KD92H6V
- Background
An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
- Indication
库欣综合征的鉴别诊断，也可用于治疗。也治疗某些肾上腺皮质肿瘤引起的肾上腺功能亢进。
- Associated Conditions
- -
- Associated Therapies
- -
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT06106295
- Locations
- 🇺🇸
Mayo Clinic Minnesota, Rochester, Minnesota, United States
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Centre Hospitalier Rouffach
- Target Recruit Count
- 14
- Registration Number
- NCT03491696
- Locations
- 🇫🇷
Hopitaux Universitares de Strasbourg, Strasbourg, Bas Rhin, France
🇫🇷Centre Hospitalier de Rouffach, Rouffach, Haut Rhin, France
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- HRA Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT02297945
- Locations
- 🇧🇪
CHU Erasme, Brussels, Belgium
🇷🇴Spitalul Universitar de Urgenta Militar Central 'Dr Carol Davila', Bucharest, Romania
🇷🇴Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
- Conditions
- Interventions
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 256
- Registration Number
- NCT01673087
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Cortisol and Nutritional Sympathetic Responsiveness
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Baker Heart Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT01620684
- Locations
- 🇦🇺
Heart Centre, Alfred Hospital, Prahran, Melbourne, Victoria, Australia
Antiglucocorticoid Augmentation of antiDepressants in Depression
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Jane Barnes
- Target Recruit Count
- 190
- Registration Number
- NCT01375920
- Locations
- 🇬🇧
Leeds Community Mental Health Team, Leeds, United Kingdom
🇬🇧Stockton Affective Disorders Service, Newcastle upon Tyne, Teesside, United Kingdom
🇬🇧Regional Affective Disorders Service, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction
- Conditions
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2008-12-31
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00567814
- Locations
- 🇺🇸
Department of Psychiatry, Psychopharmacology Research Clinic, Shreveport, Louisiana, United States
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
- Conditions
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00426608
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Metyrapone as Additive Treatment in Major Depression
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2005-08-12
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 63
- Registration Number
- NCT00125554
- Locations
- 🇩🇪
Dept. of Psychiatry and Psychotherapy, UKE, Hamburg, Germany
Cocaine-Metyrapone Interaction Study - 1
- Conditions
- First Posted Date
- 2002-04-08
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 12
- Registration Number
- NCT00033098
- Locations
- 🇺🇸
Cincinnati VA Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.